Pro Medicus Limited (ASX:PME)

ALERT: Price-sensitive ASX Announcement for PME

Current share price for PME : $163.140 -134.01 (-45.10%)⁺

Announcement

PME FY2025 results presentation

Release

14 Aug 2025 9:45AM

Price at Release

$297.150

Full Release

Summary

Pro Medicus Limited (PME), a leader in enterprise imaging and radiology information systems, reported a record financial year 2025 with significant growth across various metrics. The company achieved a 31.9% increase in revenue reaching $213 million, and a 39.2% rise in profit after tax to $115.2 million. The underlying EBIT also saw a substantial increase of 40.5% to $157.7 million, with margins at 74%. Pro Medicus remains debt-free and has a strong balance sheet, with cash and investments up by 35.5% to $210.7 million. The FY2025 highlights include signing seven new contracts totaling AUD $520 million, two large contract renewals worth AUD $130 million, and completing seven cloud-based implementations. The company also signed a significant research collaboration agreement with the University of California, San Francisco. Pro Medicus has made substantial progress in expanding its footprint in other medical specialties and artificial intelligence, thus setting a robust foundation for continued growth in the next financial year.

Key Points

Revenue increased by 31.9% to $213 million.
Profit after tax rose by 39.2% to $115.2 million.
Underlying EBIT up by 40.5%, reaching $157.7 million.
EBIT margins at 74%.
Cash and investments increased by 35.5% to $210.7 million.
Signed seven new contracts totaling AUD $520 million.
Two large contract renewals valued at AUD $130 million.
Completed seven cloud-based implementations.
Research collaboration agreement with UCSF.
Expanded operations in other medical specialties and AI.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.